In addition to directly targeting the cancer-causing driver HER2 and inhibiting its function, harnessing the innate and acquired immune systems to deal with proliferating cancer cells is a promising and active area of research for HER2-positive BC. The gene discussed is ERBB2; the disease is breast cancer.